Author: Customer Service

ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following March investor conferences:TD Cowen 46th Annual Health Care ConferenceDate:Fireside chat:Place:Webcast Link: Monday, March 2, 20262:30 p.m. ETBoston Marriott Copley Place, Boston, Mass.HereJefferies Biotech on the Beach SummitDate:Place: Tuesday, March 10, 20261 Hotel South Beach, Miami Beach, Fla.Barclays 28th Annual Global Healthcare ConferenceDate: Fireside chat: Place: Webcast Link: Wednesday, March 11, 20262:00 p.m. ETLoews Miami Beach, Miami Beach, Fla.HereInvestors interested in arranging a meeting with...

FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer ROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) —  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the U. S. Food and Drug Administration (FDA) has placed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab, an investigational, bispecific DART® molecule that targets PD-1 and CTLA-4, in patients with gynecologic cancers. Under the partial clinical hold, no new patients will be enrolled in the LINNET study until the partial hold is lifted by the FDA. Current study participants may continue to receive study drug. The FDA’s partial clinical hold was initiated following the Company’s recent notification...

Company to Transfer Listing of Its Securities to New York Stock Exchange HAUPPAUGE, N.Y., Feb. 23, 2026 (GLOBE NEWSWIRE) — Dime Community Bancshares, Inc. (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”) today announced that, subject to shareholder approval, it will change its name to “Dime Commercial Bancshares, Inc.”. The Bank’s name will change to “Dime Commercial Bank”. These changes will be effective soon after the Annual Shareholder Meeting (May 28, 2026), where there will be a vote to approve the Company’s name change. The Company is also transferring the listing of its securities to the New York Stock Exchange (“NYSE”) on or around April 7, 2026. As part of its rebrand, the Company put out an investor presentation which can be found here. ABOUT DIME COMMUNITY BANCSHARES, INC. Dime is a New...

No financing will accompany the reverse split Reverse split necessary to meet national exchange listing requirements Reverse split approved by the Company’s Shareholders and Board of DirectorsNEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) — Creatd, Inc. (OTCQB: CRTD) (“Creatd” or the “Company”) today announced that it will implement a 20:1 reverse stock split of its issued and outstanding common stock, effective February 24, 2026, as reflected in the FINRA Daily List. Beginning at the market open on February 24, 2026, Creatd’s common stock will continue to trade on the OTCQB with the number of issued and outstanding shares reduced on a 1-for-20 basis. The reverse stock split is necessary to meet national exchange listing requirements, including minimum bid price thresholds. For an interim period of 20 business days, beginning on February...

Following the successful completion of the merger of Alm. Brand and Codan, Rasmus Werner Nielsen has chosen to step down as CEO of Alm. Brand A/S. Deputy CEO and CFO Andreas Ruben Madsen is appointed as the new CEO of Alm. Brand Group effective from 1 March. Andreas Ruben Madsen has been employed with the group for ten years, the last six years as CFO and member of the Group Executive Management and, since March 2025, as Deputy CEO. Chairman of the Board of Directors Jais Valeur says: “Andreas Ruben Madsen has played a crucial role in the transformation of Alm. Brand from a financial supermarket to the strong, fully-focused Danish non-life insurer that Alm. Brand Group is today. At the same time, he has been instrumental to the development of the group’s strategy for the next three years, and it is only natural that he now takes over and...

FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall study cohort, with median rPFS of 10.1 months observed in patients who progressed on only one prior ARPI Higher tumor uptake of FG-3180, a CD46 directed PET imaging agent, demonstrated a trend towards higher probability of PSA50 response, highlighting its potential for patient selection Combination therapy had a similar safety and exposure profile to the previous FG-3246 Phase 1 monotherapy trial Results further validate key FG-3246 Phase 2 monotherapy design elements, most importantly the inclusion of patients who have progressed on only one...

LUXEMBOURG, Feb. 23, 2026 (GLOBE NEWSWIRE) — Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) (“Tenaris”) announced today that it has decided to terminate, effective on March 3, 2026, the second tranche of its Share Buyback Program announced on May 27, 2025 (the “Program”). As previously disclosed, Tenaris had entered into a non-discretionary buyback agreement with a primary financial institution for the execution of this USD 600 million second tranche of the Program. This tranche began on November 3, 2025, and was scheduled to end no later than April 30, 2026. Since the commencement of this tranche, Tenaris has repurchased 29,295,219 ordinary shares at an aggregate cost of approximately USD 583.6 million, thereby substantially completing its targeted repurchases. Tenaris has concluded that, in a context of high-volatity in...

Newport Beach, CA, Feb. 23, 2026 (GLOBE NEWSWIRE) — Bimergen Energy Corporation (“Bimergen” or the “Company”) (NYSE American: BESS, BESS.WS), a utility-scale battery energy storage systems (BESS) asset owner, project developer, and independent power provider, today announced the closing of its public offering of common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) and one accompanying warrant per common stock or Pre-Funded Warrant, at a public offering price of $4.00, for gross proceeds of $13,600,000, before deducting underwriting discounts and offering expenses. In addition, Bimergen has granted the underwriters a 45-day option to purchase up to an additional 200,000 shares of common stock (or Pre-Funded Warrants) and/or an additional 200,000 warrants to cover over-allotments, if any. The offering also...